Aveanna Healthcare (NASDAQ:AVAH) Price Target Lowered to $9.50 at Barclays

Aveanna Healthcare (NASDAQ:AVAH) had its price target reduced by Barclays from $11.00 to $9.50 in a research report report published on Wednesday,Benzinga reports. They currently have an overweight rating on the stock.

Several other equities analysts also recently issued reports on AVAH. Zacks Research downgraded Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. Weiss Ratings upgraded Aveanna Healthcare from a “hold (c)” rating to a “buy (b-)” rating in a research note on Friday, March 20th. William Blair assumed coverage on Aveanna Healthcare in a report on Monday, December 8th. They issued an “outperform” rating for the company. Raymond James Financial upgraded shares of Aveanna Healthcare from an “outperform” rating to a “strong-buy” rating and set a $13.00 price target on the stock in a research report on Friday, March 20th. Finally, BMO Capital Markets decreased their price objective on shares of Aveanna Healthcare from $11.00 to $10.00 and set an “outperform” rating on the stock in a report on Friday, March 20th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.38.

Aveanna Healthcare Stock Up 0.2%

Shares of AVAH opened at $6.62 on Wednesday. The company has a market capitalization of $1.44 billion, a P/E ratio of 6.49 and a beta of 2.07. Aveanna Healthcare has a one year low of $3.73 and a one year high of $10.32. The business’s 50 day simple moving average is $7.71 and its 200-day simple moving average is $8.46. The company has a debt-to-equity ratio of 6.62, a current ratio of 1.32 and a quick ratio of 1.32.

Insider Buying and Selling

In related news, CFO Matthew Buckhalter sold 13,512 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $7.21, for a total value of $97,421.52. Following the transaction, the chief financial officer owned 529,243 shares in the company, valued at $3,815,842.03. This trade represents a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Deborah Stewart sold 11,181 shares of Aveanna Healthcare stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $7.21, for a total value of $80,615.01. Following the completion of the sale, the chief accounting officer owned 301,807 shares of the company’s stock, valued at approximately $2,176,028.47. The trade was a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 998,595 shares of company stock worth $7,567,770. 7.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd raised its stake in shares of Aveanna Healthcare by 252.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,351 shares of the company’s stock worth $27,000 after buying an additional 2,400 shares during the last quarter. Quantbot Technologies LP bought a new position in Aveanna Healthcare in the second quarter valued at approximately $43,000. Oxford Asset Management LLP bought a new position in Aveanna Healthcare in the second quarter valued at approximately $64,000. Dynamic Technology Lab Private Ltd acquired a new stake in Aveanna Healthcare during the 2nd quarter worth $68,000. Finally, PharVision Advisers LLC acquired a new stake in Aveanna Healthcare during the 2nd quarter worth $78,000. Institutional investors own 87.96% of the company’s stock.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.